Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer
Status:
RECRUITING
Trial end date:
2030-12-01
Target enrollment:
Participant gender:
Summary
This multicenter, prospective clinical trial is designed to enroll PD-L1 expression-positive patients with stage IB1 cervical cancer who desire fertility preservation to undergo neoadjuvant chemotherapy in combination with a PD-1 inhibitor to evaluate the rate of complete pathologic remission, treatment-related adverse events, pregnancy rate, miscarriage rate, preterm birth rate, live birth rate, EFS and OS.
Phase:
PHASE2
Details
Lead Sponsor:
Tongji Hospital
Collaborators:
Anhui Provincial Cancer Hospital Beijing Friendship Hospital Gansu Cancer Hospital Qilu Hospital of Shandong University Shengjing Hospital Sichuan Cancer Hospital and Research Institute Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Third Military Medical University Tianjin Medical University West China Second University Hospital Women's Hospital School Of Medicine Zhejiang University Xiangya Hospital of Central South University Zhejiang Cancer Hospital